NANETS-ENETS Joint Symposium, 11-13 October 2012, San Diego: Call for abstracts
All ENETS Members under the age of 40 are invited and encouraged to submit an abstract for the NANETS-ENETS Joint Symposium 2012, which will be held in San Diego, California, 11-13 October 2012. Six abstracts will be selected for presentation at the San Diego conference and the selected presenting authors will be awarded coverage of their flights, hotel stay and registration fees. The deadline to submit an abstract is 30 June 2012. Please
click here to submit your work. Abstracts must be less than 300 words.
ENETS members can access information on having their hospital apply to become a certified ENETS Center of Excellence. To access more information and download the application requirements, please log in to your ENETS account (top right corner of this website).
Between 2005 and 2007, ENETS produced revisions to NET diagnosis and treatment guidelines. The Guidelines today serve clinicians worldwide in managing patient care. As well, ENETS has developed TNM classifications and Standards of Care.
Please click here to access the Guidelines, as well as the Society's published work on TNM classifications and Standards of Care.
The Benefits of ENETS Membership include
- an invitation to the ENETS annual conference (read about past conferences by clicking here)
- a reduced subscription fee to the online version of Neuroendocrinology, the official journal of ENETS
- reduced-fee or free participation in regular training programs and symposia
- regular updates on research results and upcoming events through the ENETS Newsletter
- participation in multicentered clinical trials
- password-protected access to the members' section of the ENETS homepage, which includes access to information on the ENETS Centers of Excellence program
To become a member, click here
The European Neuroendocrine Tumor Society (ENETS) is an international professional association composed of physicians and researchers, whose main area of study is related to neuroendocrine tumors.
It was founded in Frankfurt am Main on 11 March 2004.